IP Library Granted Patent US 9,949,986
Granted Patent B2
US 9,949,986 · App. 15/349,573 · Granted Apr 24, 2018

Synthetic bile acid compositions and methods

Inventors: Robert M. Moriarty (Calabasas, CA); Nathaniel E. David (Calabasas, CA); Nadir Ahmeduddin Mahmood (Calabasas, CA)
Assignee: Kythera Biopharmaceuticals, Inc.
A61K31/575A61K47/24A61K38/08A61K45/06C07J9/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,949,986
App. No.
15/349,573
Granted
Apr 24, 2018
Kind
B2
Abstract

Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.

Claims (9)

1. A method for reducing a subcutaneous fat deposit in a subject in need thereof, the method comprising administering locally to the subcutaneous fat deposit in the subject a composition comprising: a fat-dissolving effective amount of DCA

or a pharmaceutically acceptable salt thereof, wherein the DCA comprises a synthetic side chain of formula:

and at least one pharmaceutically acceptable excipient and/or carrier.

2. The method of claim 1 , wherein the DCA or the pharmaceutically acceptable salt thereof is present in the composition in an amount of about 0.1% w/v to about 2% w/v.

3. The method of claim 1 , wherein the composition further comprises phosphatidylcholine.

4. The method of claim 1 , wherein the composition does not contain phosphatidylcholine.

5. The method of claim 1 , wherein the subcutaneous fat deposit is associated with a condition selected from the group consisting of obesity, fat redistribution syndrome, eyelid fat herniation, lipomas, Dercum's disease, lipodystrophy, buffalo hump lipodystrophy, dorsocervical fat, visceral adiposity, breast enlargement, hyperadiposity, diffused body fat around trunk and arms, and fat deposits associated with cellulite.

6. The method of claim 1 , wherein the DCA salt is sodium deoxycholate.

7. The method of claim 3 , wherein the phosphatidylcholine is present in the composition in an amount of up to 5% w/v.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2021
From: MORIARTY, ROBERT M.; DAVID, NATHANIEL E.; MAHMOOD, NADIR AHMEDUDDIN
To: KYTHERA BIOPHARMACEUTICALS, INC.
Reel/Frame 056904/0887 →
MERGER AND CHANGE OF NAME Recorded Oct 17, 2019
From: KYTHERA BIOPHARMACEUTICALS, LLC; ALLERGAN SALES, LLC
To: ALLERGAN SALES, LLC
Reel/Frame 050754/0909 →
CHANGE OF NAME Recorded Oct 8, 2019
From: KYTHERA BIOPHARMACEUTICALS, INC.
To: KYTHERA BIOPHARMACEUTICALS, LLC
Reel/Frame 050672/0658 →
Continuity (6)
Continuation 14503273 · Sep 30, 2014
Continuation 13741212 · Jan 14, 2013
Continuation 12035339 · Feb 21, 2008
Provisional Application 60956875 · Aug 20, 2007
Provisional Application 60945035 · Jun 19, 2007
Related Publication 20170136040A1 · May 18, 2017